Yoodo Breaks New Ground in the Malaysian Mobile Market
MATRIXX Software today announced that Yoodo, Malaysia’s newest mobile player, has launched as the first mobile service in the country that enables customers to completely customize their mobile plan. Challenging the status quo, Yoodo is a new mobile brand that gives their customers the ultimate choice and control over their plans while delivering simple, clear and engaging customer service.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180131005338/en/
Yoodo has thrown out the rules of the mobile market and is offering customizable packages across voice, data, messaging and content with up to 1,000 combinations possible. Customers can change, upgrade or downgrade their package at any time via their mobile app. Customers don’t have to choose prepaid or contract, but rather get the best of both worlds with the ability to dynamically add-on or auto-renew as they please. Other highlights of the service include: self-registration, immediate SIM delivery, roam like home, add-on boosters, rewards, and non-intrusive, curated promotions triggered by location or spending behavior.
“Traditional mobile operators design plans based on what they want to sell the customer, developing various plans and features that don’t fit most customer’s individual needs. We’ve flipped that on its head and enabled customers to make their mobile plans work for them, by providing a real-time, on-demand service that lets people experience full control,” said Farid Yunus, Head of Yoodo.
Yoodo’s goal is to provide consumers with simpler and clearer options for cutting edge digital products and services, leading to a better overall experience. Simpler means there are fewer steps for sign up, changing plans, account inquiries, paying, disconnection and reconnection. Clearer means no hidden charges or contracts, with real-time account and spending information available at all times through the mobile app.
Powered by MATRIXX Software, Yoodo built and deployed a digital Telco infrastructure that could enable their market-entry strategy as well as their longer-term ambitions. Yoodo chose MATRIXX Software’s digital commerce platform because of its unique ability to deliver first-class digital experience to their customers, while also providing agility and innovation to their operations.
Farid from Yoodo explained further, “Our goal is to break the boundaries of the traditional mobile business, and to do so we needed systems and expertise to build a disruptive digital operating model. We chose MATRIXX Software as they are the leading supplier providing new and innovative solutions and technologies so that Telco's can leapfrog into the era of digital and mobile commerce.”
Launched in January 2018, Yoodo is an independent digital mobile service that is owned and operated by Celcom Axiata Bhd. It offers the country’s first truly customisable mobile service, with complete transparency, flexibility and customer convenience. For more information on Yoodo, log on to yoodo.com.my or look up yoodoMY on Facebook, Instagram, YouTube and Twitter.
About MATRIXX Software
Silicon Valley based MATRIXX Software is committed to helping Telco’s reinvent themselves into leaders of the digital economy. Our multi-patented MATRIXX Digital Commerce platform was built from scratch to serve as the foundation for next-generation IT architectures capable of powering rapid transformation. Through innovations in engineering, product, sales and deployment, we empower Communications Service Providers with the speed, agility and autonomy they need to give their customers modern, digital experiences.
Mercury Global Partners for MATRIXX
Natalee Gibson, +1 720-648-5784
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Game of Thrones Winter is Coming™ Launches Worldwide26.3.2019 02:00:00 EET | Tiedote
Yoozoo Games, a leading game developer and publisher, today announced the global launch of Game of Thrones Winter is Coming™ , a real-time strategy PC browser game officially licensed by Warner Bros. Interactive Entertainment under license from HBO®. The game is now available in English, with additional languages to follow. HBO, Warner Bros. Interactive Entertainment and Yoozoo Games have collaborated to recreate Westeros on a massive scale, delivering an authentic and immersive multiplayer world laid out across the Seven Kingdoms – complete with major landmarks and castles from the epic TV series. The story begins immediately following the death of Eddard Stark, when the player emerges as a new Westeros lord or lady in his stead. Strategising starts in earnest in Game of Thrones Winter is Coming as players aim to build an impenetrable base, train a victorious army and recruit faithful followers from a pool of iconic characters. As players progress, they must continue to acquire the mi
Earth Networks Announces Completion of Severe Weather Early Warning System for PAGASA26.3.2019 02:00:00 EET | Tiedote
Earth Networks announced today the completion of the Philippines’ first nationwide severe weather monitoring and alerting network with associated software services for the Philippine Atmospheric, Geophysical, and Astronomical Services Administration (PAGASA), the National Meteorological and Hydrological Services (NMHS) agency of the Republic of the Philippines. The announcement was made at the 6th annual InterMET Asia conference in Singapore. Initiated in 2017, and formally commissioned this week, the technology partnership between PAGASA and Earth Networks is the first of its kind in the Philippines and surrounding regions, powered by a network of total lightning sensors and real-time automatic weather stations for mesoscale monitoring. Installed and operated together with Philippines partner West Point Engineering, the 10-year program includes: Real-time lightning detection powered by the Earth Networks Total Lightning Network On-the-ground weather monitoring via the Earth Networks W
bluebird bio Statement on European Regulatory Status of LentiGlobin™26.3.2019 01:40:00 EET | Tiedote
A third party press release was issued today stating that the EMA (European Medicines Agency) issued an approval for the conditional Marketing Authorization Application (MAA) for LentiGlobin™, bluebird bio’s investigational gene therapy for the treatment of transfusion dependent β-thalassemia (TDT). LentiGlobin for TDT is scheduled to be reviewed as part of the CHMP (Committee on Human Medicinal Products) meeting from March 25 – 28, however no opinion has been issued by the CHMP. If the CHMP’s opinion is issued it would then be reviewed by the European Commission (EC), which has the authority to grant approval for the use of LentiGlobin in the EU. About bluebird bio, Inc. bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working
Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis25.3.2019 23:30:00 EET | Tiedote
Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for ozanimod for the treatment of adults with relapsing forms of multiple sclerosis (RMS). Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator, which binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5). The pivotal efficacy and safety data provided in the application result from the SUNBEAM™ and RADIANCE™ Part B phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled trials. “New oral treatment options with differentiated profiles like ozanimod are needed to help address an unmet need for people with relapsing forms of MS,” said Jay Backstrom, M.D., Chief Medical Officer for Celgene. “With concurrent applications in the U.S. and EU, we look forward to advancing this promising medicine through the regulatory review process to provide a new option for the treatment of RMS in
AVLT and UKTS Announce the European Medicines Agency’s Approval of the Conditional Marketing Authorization Application for Zynteglo™ (Previously Known as Lentiglobin™) Gene Therapy for the Treatment of Transfusion Dependent Beta Thalassaemia25.3.2019 22:50:00 EET | Tiedote
Associazione Veneta Lotta alla Talassemia (AVLT) and the UK Thalassaemia Society (UKTS) announced today that the European Medicines Agency (EMA) has approved bluebird bio’s application for Conditional Marketing Authorization (cMAA) of their product Zynteglo™, a gene therapy for the treatment of adolescents and adults with transfusion-dependent β-thalassaemia (TDT) who do not have a β0/β0 genotype. As a result of this marketing authorisation, Zynteglo™ is now approved for use in all European countries covered by the European Medicines Agency. Zynteglo™ has been given ‘conditional authorisation’. This means that there is more evidence to be submitted, which the company is required to provide under specific obligations. Every year, the EMA will review any new information that becomes available. “People living with transfusion-dependent β-thalassaemia have a reduced life expectancy, requiring life-long frequent blood transfusions that are life-saving but may lead to complications, includin
Historic Partnership between the Weizmann Institute of Science and Institut Curie25.3.2019 19:54:00 EET | Tiedote
On March 22, the Weizmann Institute of Science in Rehovot, Israel, and Institut Curie in Paris, France, two major world-class research institutes, signed an historic partnership that will allow their teams to work closely together to improve knowledge in the field of life sciences, particularly in the areas of physics and chemistry, and most specifically - in the field of cancer research. This is a milestone in the history of these two institutes that have been working together for 15 years, particularly in the field of biophysics. Collaborative research programs This partnership will extend to many disciplines, including physics, chemistry, cellular biology, epigenetics, genetics, immunology and single cell approaches, imagery and data collection. The complementarity of the research between the various groups at Institut Curie and at the Weizmann Institute has been recognized in particular at the occasion of joint scientific workshops held regularly alternatively in Paris and Rehovot.
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme